Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Monthly Recap: China Pharmaceutical Regulatory Updates | June 2022 Check out the pharmaceutical regulatory updates in China: 1.CDE Issues the 2021 China Drug Evaluation Report; 2. CDE Publishes the 2021 Clinical Trial Report; 3. CDE Consults on Communication Procedures for Pediatric Drug Applicants...
Jul 06, 2022
China Emphasizes Rare Disease & Pediatric Drugs in Adjusting the 2022 National Reimbursement Drug List (NRDL) On June 29, 2022, China NHSA issued the Work Plan for Adjusting the 2022 National Reimbursement Drug List (NRDL). NRDL is a list of drugs covered by the basic national insurance for healthcare, employment injury, and maternity.
Jul 04, 2022
Biogen's Drug for Rare Disease SMA Gets Access to More Patients in China Due to NRDL In December 2021, Biogen cut the price of Spinraza (Nusinersen Sodium Injection) from 700,000 yuan per dose to 33,000 yuan per dose to get a place in China’s National Reimbursement Drug List (NRDL). The move makes Spinraza gain access to more spinal muscular atrophy (SMA) patients in China.
Feb 14, 2022
Best-selling Ophthalmic Drugs in China | Market Wrap 2021 The year 2021 has seen a remarkable growth of the ophthalmic drug market in China. The market size of chemical drugs for eye diseases is estimated to exceed 3.5 billion yuan (circa 549 million USD), with a year-on-year growth of 1.89%.
Jan 10, 2022
China Adds 74 Drugs to National Reimbursement Drug List (NRDL) On Dec. 3, China released its 2021 National Reimbursement Drug List (NRDL). NRDL is a list of drugs allowable for reimbursement by the national social health insurance fund under the social security system which has covered more than 1.36 billion people in China by the end of 2020.
Dec 08, 2021
China Promotes Distribution of Medicare-covered Drugs Through "Double Channel" China permits qualified drug stores to sell prescription drugs included in the National Reimbursement Drug List. At these drug stores, people can enjoy the same medical care payment coverage with hospitals. The policy intends to add another sales channel for the drugs outside hospitals, especially for the newly listed drugs through centralized procurement.
May 24, 2021
China's 2020 National Reimbursement Drug List Includes 119 Additional Drugs China's National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the 2020 Edition of the National Reimbursement Drug List (NRDL) on Dec. 28, 2020, which will take effect on Mar. 1, 2021.
Mar 08, 2021
China's Social Medical Insurance to Cover More Drugs for Rare Diseases On Dec. 28, 2020, the National Healthcare Security Administration and Ministry of Human Resources and Social Security issued the 2020 Edition of the National Reimbursement Drug List (NRDL).
Mar 08, 2021
- 2021 China CDE Drug Evaluation Report
- Monthly Report: New Drug Approvals in China | June 2022
- China Kicks off the 7th Round of Volume-based Procurement (VBP) of Drugs
- China Emphasizes Rare Disease & Pediatric Drugs in Adjusting the 2022 National Reimbursement Drug List (NRDL)
- Licensing Deals Involving Chinese Pharma Companies in H1 2022